Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).

Authors

Pieter Sonneveld

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Pieter Sonneveld , Evangelos Terpos , Meletios A. Dimopoulos , Jon Ukropec , Elena Smith , Nienke Houkes , Jordan Mark Schecter , Efstathios Kastritis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.

First Author: Andrew Spencer

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

First Author: Saad Zafar Usmani

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.

First Author: Maria-Victoria Mateos

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).

First Author: Paul G. Richardson